Health Canada Approves First Levothyroxine Oral Solution

BioSyent Inc. has received Health Canada approval for Thyconvi, a levothyroxine oral solution—marking the first such formulation available in the country. The approval addresses a gap in treatment options for hypothyroidism and thyroid-stimulating hormone suppression, conditions affecting hundreds of thousands of Canadians.

Levothyroxine is one of the most commonly prescribed medications in Canada, used by patients who have had their thyroid removed or whose thyroid doesn't produce enough hormone. Until now, patients have relied on tablets. An oral solution offers advantages for those who have difficulty swallowing pills—elderly patients, people with dysphagia, or those taking multiple medications that interact with solid formulations.

BioSyent, a Mississauga-based specialty pharmaceutical company, holds an exclusive license to distribute Thyconvi in Canada. The approval signals Health Canada's recognition that liquid formulations of essential medications can improve treatment adherence and expand access for vulnerable populations. Thyconvi will be available through Canadian pharmacies, with pricing and coverage decisions to follow.